Conserving scarce resources: Willingness of health insurance enrollees to choose cheaper options

Journal of Law, Medicine and Ethics

Volumn 32, Issue 3, 2004, Pages 496-499

  Hurst, Samia A ^a   Teagarden, J Russell ^b   Garrett, Elizabeth ^c   Emanuel, Ezekiel J ^d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Clin Practices Therapeut Medco H

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CONTROLLED STUDY; DECISION MAKING; FEMALE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MALE; PRESCRIPTION; REVIEW;

EID: 4944249693     PISSN: 10731105     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2004.tb00162.x     Document Type: Review

References (21)

1. "OECD Health Data 2002: a Comparative Analysis of 30 Countries" CD-Rom, OECD, Paris 2002.
2. P. Zweifel and F. Breyer F, Health Economics (Oxford, New York: Oxford University Press, 1997); H.H. Hiatt, "Protecting the Medical Commons: Who is Responsible?" N. Engl. J. Med. 293, no. 5 (1975): 235-41; K.J. Arrow, "Uncertainty and the Welfare Economics of Medical Care," Journal of Health, Politics and Policy Law 26, no. 5 (2001): 851-83.
3. P. Zweifel and F. Breyer F, Health Economics (Oxford, New York: Oxford University Press, 1997); H.H. Hiatt, "Protecting the Medical Commons: Who is Responsible?" N. Engl. J. Med. 293, no. 5 (1975): 235-41; K.J. Arrow, "Uncertainty and the Welfare Economics of Medical Care," Journal of Health, Politics and Policy Law 26, no. 5 (2001): 851-83.
4. P. Zweifel and F. Breyer F, Health Economics (Oxford, New York: Oxford University Press, 1997); H.H. Hiatt, "Protecting the Medical Commons: Who is Responsible?" N. Engl. J. Med. 293, no. 5 (1975): 235-41; K.J. Arrow, "Uncertainty and the Welfare Economics of Medical Care," Journal of Health, Politics and Policy Law 26, no. 5 (2001): 851-83.
5. P. Ubel, Pricing Life: Why It's Time for Health Care Rationing (Cambridge, Massachusetts: The MIT Press, 2001).
6. M.A. Hall, Making Medical Spending Decisions (Oxford: Oxford University Press, 1997).
7. K. Levit, et. al., "Trends in U.S. Health Care Spending, 2001," Health Affairs 22, no. 1 (2003): 154-64.
8. S. Heffler, et. al., "Health Spending Projections for 2002-2012," Health Affairs Web Exclusive (February 7, 2003): W3-54 to W3-65, at 〈http:// content.healthaffairs.org/cgi/content/full/hlthaff.w3. 54v1/DC1〉 (last visited August 6, 2004).
9. S.M. Ess, S. Schneeweiss and T.D. Szucs, "European Healthcare Policies for Controlling Drug Expenditure," PharmacoEconomics 21, no. 2 (2003): 89-103; D. Jacobson, "Effective Strategies for Managing Pharmacy Benefits," Healthcare Financial Management 55, no. 3 (2001): 41-2.
10. S.M. Ess, S. Schneeweiss and T.D. Szucs, "European Healthcare Policies for Controlling Drug Expenditure," PharmacoEconomics 21, no. 2 (2003): 89-103; D. Jacobson, "Effective Strategies for Managing Pharmacy Benefits," Healthcare Financial Management 55, no. 3 (2001): 41-2.
11. P.A. Ubel and S.D. Goold, "'Rationing' Health Care: Not All Definitions are Created Equal," Archives of Internal Medicine 158, no. 3 (1998): 209-14; D.M. Eddy, "What Care is 'Essential'? What Services are 'Basic'?" JAMA 265, no. 6 (1991): 782, 786-8.
12. P.A. Ubel and S.D. Goold, "'Rationing' Health Care: Not All Definitions are Created Equal," Archives of Internal Medicine 158, no. 3 (1998): 209-14; D.M. Eddy, "What Care is 'Essential'? What Services are 'Basic'?" JAMA 265, no. 6 (1991): 782, 786-8.
13. P. Danielson, "Competition Among Cooperators: Altruism and Reciprocity. Proceedings of the National Academy of Sciences of the United States of America 99, Suppl. 3 (2002): 7237-42; M. Milinski, D. Semmann and H.J. Krambeck, "Reputation Helps Solve the 'Tragedy of the Commons,'" Nature 415, no. 6870 (2002): 424-6.
14. P. Danielson, "Competition Among Cooperators: Altruism and Reciprocity. Proceedings of the National Academy of Sciences of the United States of America 99, Suppl. 3 (2002): 7237-42; M. Milinski, D. Semmann and H.J. Krambeck, "Reputation Helps Solve the 'Tragedy of the Commons,'" Nature 415, no. 6870 (2002): 424-6.
15. N. Daniels and J. Sabin, "Limits to Health Care: Fair Procedures, Democratic Deliberation, and the Legitimacy Problem for Insurers," Philosophy of Public Affairs 26, no. 4 (1997): 303-50; N. Daniels, J.R. Teagarden, J.E. Sabin, "An Ethical Template for Pharmacy Benefits," Health Affairs 22, no. 1 (2003): 125-37; E.J. Emanuel, "Patient v. Population: Resolving the Ethical Dilemmas Posed by Treating Patients as Members of Populations," in M. Danis, C.M. Clancy and L. Churchill L, eds., Ethical Dimensions of Health Policy (Oxford, New York: Oxford University Press, 2002): 227-245.
16. N. Daniels and J. Sabin, "Limits to Health Care: Fair Procedures, Democratic Deliberation, and the Legitimacy Problem for Insurers," Philosophy of Public Affairs 26, no. 4 (1997): 303-50; N. Daniels, J.R. Teagarden, J.E. Sabin, "An Ethical Template for Pharmacy Benefits," Health Affairs 22, no. 1 (2003): 125-37; E.J. Emanuel, "Patient v. Population: Resolving the Ethical Dilemmas Posed by Treating Patients as Members of Populations," in M. Danis, C.M. Clancy and L. Churchill L, eds., Ethical Dimensions of Health Policy (Oxford, New York: Oxford University Press, 2002): 227-245.
17. N. Daniels and J. Sabin, "Limits to Health Care: Fair Procedures, Democratic Deliberation, and the Legitimacy Problem for Insurers," Philosophy of Public Affairs 26, no. 4 (1997): 303-50; N. Daniels, J.R. Teagarden, J.E. Sabin, "An Ethical Template for Pharmacy Benefits," Health Affairs 22, no. 1 (2003): 125-37; E.J. Emanuel, "Patient v. Population: Resolving the Ethical Dilemmas Posed by Treating Patients as Members of Populations," in M. Danis, C.M. Clancy and L. Churchill L, eds., Ethical Dimensions of Health Policy (Oxford, New York: Oxford University Press, 2002): 227-245.
18. A. Leibowitz, W.G. Manning and J.P Newhouse, "The Demand for Prescription Drugs as a Function of Cost-Sharing," Social Science and Medicine 21, no. 10 (1985): 1063-9; T.S. Rector, et. al., "Effect of Tiered Prescription Co-payments on the Use of Preferred Brand Medications," Medical Care 41, no. 3 (2003): 398-406; B. Motheral and K.A. Fairman, "Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization," Medical Care 39, no. 12 (2001): 1293-304; B. Motheral, R. Henderson, "The Effect of a Copay Increase on Pharmaceutical Utilization, Expenditures, and Treatment Continuation," American Journal of Managed Care 5 (November 1999): 1383-94.
19. A. Leibowitz, W.G. Manning and J.P Newhouse, "The Demand for Prescription Drugs as a Function of Cost-Sharing," Social Science and Medicine 21, no. 10 (1985): 1063-9; T.S. Rector, et. al., "Effect of Tiered Prescription Co-payments on the Use of Preferred Brand Medications," Medical Care 41, no. 3 (2003): 398-406; B. Motheral and K.A. Fairman, "Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization," Medical Care 39, no. 12 (2001): 1293-304; B. Motheral, R. Henderson, "The Effect of a Copay Increase on Pharmaceutical Utilization, Expenditures, and Treatment Continuation," American Journal of Managed Care 5 (November 1999): 1383-94.
20. A. Leibowitz, W.G. Manning and J.P Newhouse, "The Demand for Prescription Drugs as a Function of Cost-Sharing," Social Science and Medicine 21, no. 10 (1985): 1063-9; T.S. Rector, et. al., "Effect of Tiered Prescription Co-payments on the Use of Preferred Brand Medications," Medical Care 41, no. 3 (2003): 398-406; B. Motheral and K.A. Fairman, "Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization," Medical Care 39, no. 12 (2001): 1293-304; B. Motheral, R. Henderson, "The Effect of a Copay Increase on Pharmaceutical Utilization, Expenditures, and Treatment Continuation," American Journal of Managed Care 5 (November 1999): 1383-94.
21. A. Leibowitz, W.G. Manning and J.P Newhouse, "The Demand for Prescription Drugs as a Function of Cost-Sharing," Social Science and Medicine 21, no. 10 (1985): 1063-9; T.S. Rector, et. al., "Effect of Tiered Prescription Co-payments on the Use of Preferred Brand Medications," Medical Care 41, no. 3 (2003): 398-406; B. Motheral and K.A. Fairman, "Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization," Medical Care 39, no. 12 (2001): 1293-304; B. Motheral, R. Henderson, "The Effect of a Copay Increase on Pharmaceutical Utilization, Expenditures, and Treatment Continuation," American Journal of Managed Care 5 (November 1999): 1383-94.